Source:http://linkedlifedata.com/resource/pubmed/id/10338045
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1999-7-6
|
pubmed:abstractText |
In the present study we have used cell culture assays in order to assess the damage in the haematopoietic system 1 year after peripheral blood stem cell transplantation (PBSCT), and to establish at what level, haematopoietic progenitor cells (HPC) or stroma, this damage occurs. Thirty-one patients, nine breast cancer (BC), 17 non-Hodgkin lymphoma (NHL) and five Hodgkin disease (HD), who had received autologous PBSCT were included. Forty-eight normal subjects who had given informed consent were used as controls. Results were also compared with a matched group of patients (25 cases) prior to PBSCT. Progenitor cells were analysed using CFU-GM and plastic adherent delta (Pdelta) assays. Long-term bone marrow cultures (LTBMC) in one and two stages were established. One year after transplant both the number of committed progenitor cells and the CFU-GM production in LTBMC were significantly reduced in the three groups of patients when compared with controls (P < 0.05 or P < 0.01). Two-stage LTBMC experiments showed that the impairment in CFU-GM production was due to damage in both patients' stroma and haematopoietic progenitor cells (HPC). All patients, except those with HD, showed a decreased stromal layer confluence (P < 0.05), with significant differences in cell composition as compared to normal bone marrow (P = 0.001). When all these variables were compared with pretransplant results, we observed that stroma formation was significantly lower after PBSCT (P < 0.05), while the number of progenitor cells analysed by the Pdelta assay was significantly increased (P < 0.05). We can conclude that even 1 year after PBSCT, both the committed HPC and BM stroma remain damaged.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0268-3369
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
901-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10338045-Adolescent,
pubmed-meshheading:10338045-Adult,
pubmed-meshheading:10338045-Breast Neoplasms,
pubmed-meshheading:10338045-Cell Culture Techniques,
pubmed-meshheading:10338045-Female,
pubmed-meshheading:10338045-Hematopoiesis,
pubmed-meshheading:10338045-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10338045-Hematopoietic Stem Cells,
pubmed-meshheading:10338045-Hodgkin Disease,
pubmed-meshheading:10338045-Humans,
pubmed-meshheading:10338045-Lymphoma, Non-Hodgkin,
pubmed-meshheading:10338045-Male,
pubmed-meshheading:10338045-Middle Aged,
pubmed-meshheading:10338045-Stromal Cells,
pubmed-meshheading:10338045-Time Factors,
pubmed-meshheading:10338045-Transplantation, Autologous
|
pubmed:year |
1999
|
pubmed:articleTitle |
Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation.
|
pubmed:affiliation |
Servicio y Cátedra de Hematología, Hospital Universitario y Universidad de Salamanca, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|